Terms: = Ovarian cancer AND DDX6, P54, 1656, ENSG00000110367, HLR2, P26196, RCK, FLJ36338 AND Prognosis
5 results:
1. CX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer.
Shao D; Zhou H; Yu H; Zhu X
Medicine (Baltimore); 2024 Jan; 103(3):e36891. PubMed ID: 38241595
[TBL] [Abstract] [Full Text] [Related]
2. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.
Pellarin I; Dall'Acqua A; Gambelli A; Pellizzari I; D'Andrea S; Sonego M; Lorenzon I; Schiappacassi M; Belletti B; Baldassarre G
Oncogene; 2020 May; 39(22):4390-4403. PubMed ID: 32332923
[TBL] [Abstract] [Full Text] [Related]
3. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract] [Full Text] [Related]
4. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients.
Zhao M; Li S; Zhou L; Shen Q; Zhu H; Zhu X
Life Sci; 2018 Feb; 194():34-39. PubMed ID: 29247747
[TBL] [Abstract] [Full Text] [Related]